These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20965606)

  • 41. Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.
    Fanning J; Hossler CA; Kesterson JP; Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2012 Feb; 124(2):319-24. PubMed ID: 22037317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opioids and differentiation in human cancer cells.
    Zagon IS; McLaughlin PJ
    Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma.
    Zagon IS; Smith JP; Conter R; McLaughlin PJ
    Int J Mol Med; 2000 Jan; 5(1):77-84. PubMed ID: 10601579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Featured Article: Serum [Met
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2017 Sep; 242(15):1524-1533. PubMed ID: 28766982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting OGF/OGFR signal to mitigate doxorubicin-induced cardiotoxicity.
    Chen X; Jian D; Xing J; Cheng X; Wang C; Wang C; Pan J; Qi X; Wang S; Li Z; Liu Y; Jian L; Tang H
    Free Radic Biol Med; 2024 Oct; 223():398-412. PubMed ID: 39122201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid growth factor regulates the cell cycle of human neoplasias.
    Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
    Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck.
    McLaughlin PJ; Stack BC; Levin RJ; Fedok F; Zagon IS
    Cancer; 2003 Apr; 97(7):1701-10. PubMed ID: 12655527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
    McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS
    Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy of cancer via mediation of cytotoxic T lymphocytes by methionine enkephalin (MENK).
    Li W; Chen W; Herberman RB; Plotnikoff NP; Youkilis G; Griffin N; Wang E; Lu C; Shan F
    Cancer Lett; 2014 Mar; 344(2):212-22. PubMed ID: 24291668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    Qu N; Wang X; Meng Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105723. PubMed ID: 31408839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duration of opioid receptor blockade determines biotherapeutic response.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.
    Sassani JW; Mc Laughlin PJ; Zagon IS
    J Diabetes Res; 2016; 2016():9703729. PubMed ID: 27703986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice.
    McLaughlin PJ; Levin RJ; Zagon IS
    Cancer Lett; 2003 Sep; 199(2):209-17. PubMed ID: 12969794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
    McLaughlin PJ; Stucki JK; Zagon IS
    Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer.
    Goldenberg D; Zagon IS; Fedok F; Crist HS; McLaughlin PJ
    Thyroid; 2008 Nov; 18(11):1165-70. PubMed ID: 19014324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor.
    Zagon IS; Kreiner S; Heslop JJ; Conway AB; Morgan CR; McLaughlin PJ
    Int J Oncol; 2008 Aug; 33(2):317-23. PubMed ID: 18636152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.